Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cloudbreak PharmaHKSE:02592 +2.16%11 Buyback Yield % is -55.57 as of Sep. 04, 2026. GuruFocus rates HKSE:02592 with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 699 Biotechnology companies, Cloudbreak Pharma ranks worse than 84.41% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Cloudbreak Pharma's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02592 vs VRTX, REGN, MRNA: Buyback Yield % Comparison
For the Biotechnology subindustry, Cloudbreak Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cloudbreak Pharma Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cloudbreak Pharma's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Cloudbreak Pharma's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cloudbreak Pharma (HKSE:02592) has a Buyback Yield % of -55.57 as of Sep. 04, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cloudbreak Pharma and its competitors. According to the industry distribution chart, Cloudbreak Pharma ranks #590 out of 699 companies in the Biotechnology industry, placing it in the top 84.4%.
Is Cloudbreak Pharma's Buyback Yield % too high?
Cloudbreak Pharma's current Buyback Yield % is -55.57. Based on the distribution chart, Cloudbreak Pharma ranks #590 out of 699 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cloudbreak Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Cloudbreak Pharma's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cloudbreak Pharma ranks #590 out of 699 companies for Buyback Yield %. This places Cloudbreak Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cloudbreak Pharma and its competitors. Cloudbreak Pharma's current Buyback Yield % is -55.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cloudbreak Pharma stock overvalued right now?
Cloudbreak Pharma (HKSE:02592) has a current Buyback Yield % of -55.57. The current Buyback Yield % is -55.57. Cloudbreak Pharma's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Cloudbreak Pharma (HKSE:02592), the current Buyback Yield % is -55.57 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cloudbreak Pharma Inc is engaged in research and development of ophthalmology biotechnology. The company is a clinical-stage ophthalmology biotechnology company focused on developing treatments for ophthalmic diseases through the proprietary drug discovery and development capabilities, with operations based in the United States and China. The pipeline currently consists of nine drug candidates targeted for treatment of anterior and posterior ophthalmic diseases, including five clinical-stage and four pre-clinical stage candidates. The drugs in the pipeline include CBT-001, CBT-004, CBT-009, and CBT-199.
11GF Score
Get the complete analysis for HKSE:02592
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02592 has been successfully added to your 
